Sun Q3 Profits Dive, Halol Resolution Stays Pivotal To Trigger Reset

 
• By Anju Ghangurde

Sun Pharma reported a sharp decline in Q3 profits, dented by tax adjustments related to changes in US tax rates and continuing pricing pressures there. With Q4 revenues expected to to be "similar” to Q3, all eyes are on the Halol site making the compliance cut and the upcoming PDUFA date for Sun’s psoriasis asset.

Pharma pills
US PRICING PRESSURE CONTINUES TO WEIGH DOWN SUN'S EARNINGS

More from Business

More from Scrip